Search Results
Jul 15, 2026, 22:20 ET 標志性牛車水資產重新上市，意向價為4500萬新元，為投資者提供一個難得的機會，可以一次性擁有三棟相連的保留店屋
Comparative Market Analysis Table）The Platinum 物業視頻鏈接：https://youtu.be/Cd4ogZeNOXA關於 Brilliance Capital Pte. Ltd.Brilliance Capital Pte. Ltd. 是一家領先的房地產代理機構，專注於為新加坡及全球的高淨值人士、家族辦公室、房地產發展商及機構投資者提供度身定制的房地產顧問及交易服務。公司由 Sammi
More news about: Brilliance Capital
Jul 15, 2026, 09:01 ET Determinate Systems Achieves FedRAMP High Authorization Through Partnership with Knox Systems
the artifact levelTrusted publishing and provenance controls, including precise versioning and publishing restricted to authorized CI/CD systemsFaster builds and deployments through binary caching that skips redundant CI builds and supports zero-evaluation deployments in
More news about: Knox Systems, Inc
Jul 14, 2026, 08:00 ET BMC Brings Governed AI Agents to Enterprise Workflows and Mainframe Operations
vulnerabilities and exposures (CVEs) along with affected applications are identified quickly via a software bill of materials (SBOM) from directly within the CI/CD pipeline. Acting as an ingredient label, security and audit teams get component visibility, allowing developers to keep shipping code.Increase
More news about: BMC Software, Inc.
Jul 14, 2026, 08:00 ET Oracle Introduces AI-Native Builder Experience to Create and Run Agentic Applications in Oracle Fusion Applications
AI coding assistants such as Codex, Claude Code, and other Oracle tools, alongside Git-based lifecycle management, local validation, debugging, and CI/CD workflows.Access reusable developer resources: Helps developers and partners accelerate agentic application development with ready-to-use
More news about: Oracle
Jul 14, 2026, 06:00 ET Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
(SP001) is a third-generation, humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L, an upstream immune activation signal involved in B-cell, antigen-presenting cell, and platelet biology. By blocking CD40L, IBI355 has the potential to provide a targeted non-B-cell-depleting treatment across multiple
More news about: Innovent Biologics
Jul 13, 2026, 08:01 ET Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
(LAI)—that have been associated in published research with improved responses to immunotherapy.Increases in total T cells, CD4 and CD8 T-cell populations, and tumor-specific CD137-positive T cells in all three participants, with these changes generally persisting through the eight-week follow-up period.Taken
More news about: Aethlon Medical, Inc.
Jul 13, 2026, 04:56 ET Leads Biolabs Announces Multiple Studies Selected for ESMO 2026, Highlighting the Growing Global Competitiveness of Its Core Pipeline
LBL-034 is a bispecific T-cell engager (TCE) that targets both GPRC5D and CD3, developed using the Company's proprietary LeadsBody platform. Designed with a 2:1 binding format—two sites for GPRC5D and one for CD3—LBL-034 can selectively target GPRC5D+ cancer cells, conditionally activate T cells,
More news about: Leads Biolabs
Jul 13, 2026, 00:00 ET Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102
More news about: Antengene Corporation Limited
Jul 10, 2026, 04:53 ET Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
vitro efficacy evaluation, as well as druggability assessment. It has also developed multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone
More news about: Nanjing Leads Biolabs Co., Ltd.
Jul 09, 2026, 12:00 ET CIQ Ascender Pro Gives Enterprise Linux Automation the Power to Proactively Fix the Underlying Infrastructure
Ascender Galaxy Proxy started as a fix for a real problem: public Ansible Galaxy responses can be slow or unavailable, and that drags down CI/CD pipelines and project syncs that depend on them. Galaxy Proxy sits between Ansible and Galaxy and caches every response, not just collection downloads,
More news about: CIQ
Jul 09, 2026, 10:46 ET Global Pharmacogenomic Testing Service Market to Register Stunning Growth at a CAGR of ~12% by 2034 | DelveInsight
Technologies plc., Psomagen, Inc., 10x Genomics, Takara Bio Inc., Zymo Research Corporation, NuGEN Technologies, Inc. (Tecan Trading AG), Vela Diagnostics, CD Genomics, HTG Polymerase Chain Reaction, Inc., and others.
More news about: DelveInsight Business Research, LLP
Jul 09, 2026, 10:31 ET Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
target the CD20 protein expressed on the surface of lymphoma and leukemia cells. As a type II anti-CD20 antibody, it exhibits greater antibody-dependent cellular cytotoxicity and stronger direct cell-killing activity compared with conventional CD20 antibodies. After binding to CD20, obinutuzumab
More news about: DelveInsight Business Research, LLP
Jul 09, 2026, 10:01 ET B-Cell Depletion Therapy Market to Reach USD 62.6 Billion by 2036, Growing at an 8.9% CAGR as Next-Generation Immunotherapy Adoption Accelerates
USD 62.6 BillionForecast CAGR (2026–2036): 8.9%Forecast Period: 2026–2036Leading Product Type: Anti-CD20 Monoclonal Antibodies (70% share)Leading Application: Autoimmune Diseases (60% share)Leading End User: Hospital Infusion
More news about: Future Market Insights
Jul 09, 2026, 07:00 ET Kasm Technologies and Dispersive Announce General Availability of Stealth Networking Workspace Registry for Kasm Workspaces 1.19
Networking embedded at the workspace layer, available to the Kasm community with reduced operational lift through the Kasm Workspace Registry and CI/CD pipeline support.
More news about: Kasm Technologies
Jul 08, 2026, 21:13 ET HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
anchors and become a broader combination asset for difficult-to-treat solid tumors.HCB101 is a clinical-stage SIRPα-Fc fusion protein targeting the CD47/SIRPα pathway, designed to enhance macrophage-mediated anti-tumor activity. HanchorBio has been developing the asset with gastric cancer as an important
More news about: HanchorBio Inc.
Jul 08, 2026, 12:00 ET VESA Introduces DisplayHDR True Black 1400 to Certify Next-Generation OLED Displays for Professional HDR Content Creation
Black tier to date, requiring certified displays to achieve at least 1400 cd/m² peak luminance while maintaining black levels as low as 0.0005 cd/m². The new tier also raises full-screen luminance performance to at least 700 cd/m², representing a significant advancement in sustained HDR brightness while
More news about: Video Electronics Standards Association (VESA)
Jul 08, 2026, 09:00 ET The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
ELDN)Eledon Pharmaceuticals (NASDAQ: ELDN) attacks the transplant-rejection problem from the immune side. Its lead antibody tegoprubart targets the CD40 Ligand pathway to protect transplanted tissue, and in an investigator-initiated islet-transplant trial at the University of Chicago Medicine, all evaluable
More news about: USA News Group
Jul 07, 2026, 23:05 ET 하이크비전, 네트워크 카메라로 업계 최초 EUCC 인증 획득
항저우, 중국 2026년 7월 8일 /PRNewswire/ -- 하이크비전(Hikvision)이 자사의 DeepinView 네트워크 카메라 시리즈(iDS-2CD7x)가 유럽 공통 평가기준 기반의 사이버보안 인증제도(The European Cybersecurity Scheme on Common Criteria, 이하 EUCC) 인증을 성공적으로 획득했다고 발표했다. 이번 이정표는 CCTV 카메라 부문에서 세계 최초로 이 권위 있는 인증을 획득한 제품이 탄생했음을 의미하며, 강력한 제품 보안과 규정을 준수하는 디지털 거버넌스에 대한
More news about: Hikvision
Jul 07, 2026, 10:00 ET Heidrick & Struggles Leaders Jeff Sanders and Kelly O. Kay Publish Show Up to Win, a Practical Guide for Navigating Paths to New Executive Leadership Roles
KayPublisher: Harvard Business Review PressPublication Date: July 7, 2026Formats: Kindle, Audiobook, Hardcover, Audio CDISBN: 979-8-89279-213-4Purchase:
More news about: Heidrick & Struggles
Jul 07, 2026, 07:00 ET John Chiminski, Former Catalent Chair and CEO, to Serve as CD&R Operating Advisor
July 7, 2026 /PRNewswire/ -- CD&R (or the "Firm") today announced that John Chiminski, former Chair and Chief Executive Officer of Catalent, Inc., has been engaged as an Operating Advisor to CD&R funds. John brings more than three decades of leadership experience
More news about: CD&R
Jul 07, 2026, 06:40 ET Train Battery Market worth $551.1 million by 2033 | MarketsandMarkets™
demand.The nickel-cadmium batteries segment is expected to account for the largest market share during the forecast periodNickel-cadmium (Ni-Cd) batteries hold the largest share of the global train battery market because they are the preferred technology for auxiliary and backup power applications
More news about: MarketsandMarkets
Jul 07, 2026, 03:14 ET Kanazawa University research: Watching Molecules Change Shape in Slow Motion
process occurred slowly, the researchers were able to monitor the intermediate stages using nuclear magnetic resonance (NMR) and circular dichroism (CD) spectroscopy. X-ray crystallography and theoretical calculations were used to characterize the initial and final molecular states. Together, these complementary
More news about: Kanazawa University
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
sites.CD20-negative diseaseThere are limited data available on patients with CD20-negative DLBCL and patients with CD20-negative FL treated with Tepkinly, and it is possible that patients with CD20-negative DLBCL and CD20-negative FL may have less benefit compared to patients with CD20-positive
More news about: AbbVie
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
sites.CD20-negative diseaseThere are limited data available on patients with CD20-negative DLBCL and patients with CD20-negative FL treated with Tepkinly, and it is possible that patients with CD20-negative DLBCL and CD20-negative FL may have less benefit compared to patients with CD20-positive
More news about: AbbVie
Jul 06, 2026, 11:19 ET A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
its pipeline beyond its current oncology focus over time.The update arrives as GT Biopharma's clinical programs advance: GTB-3650 (Phase 1, CD33-expressing blood cancers) and GTB-5550 (Phase 1, B7-H3-expressing solid tumors), with the first GTB-5550 patient dosed in May 2026, all built on the
More news about: American News Group